Stonking Small Caps: first acquisition expands services
This fast-growing leader in the testing of infectious diseases using human challenge studies announced a first acquistion. With a highly supportive order book, strong cash position and move to a larger and much improved facility, the future continues to look bright for our Stonking Small Cap.
Human Challenge Trials (HCTs), in which healthy volunteers are deliberately infected with a pathogen to study the course of a disease and the effectiveness of potential treatments, are a valuable tool for developing new vaccines and treatments for infectious diseases.
The fast-growing AIM company covered below is developing a leading position in HCTs and has recently announced excellent interim results.
It provides end-to-end early clinical development services for a broad and long-standing client base of global…
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
- Podcasts
Previous article Next article
